---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016870"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:01:02.656590+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC reports Q2 2022 cash $237.8M; three Phase 1 readouts expected 1H 2023

## Summary
- Cash and investments $237.8M as of June 30, 2022; funds operations into 2H 2024.
- R&D expenses $13.8M for Q2 2022, down from $15.5M in Q2 2021, mainly on lower ORIC-101 costs.
- G&A expenses $6.9M for Q2 2022, up from $5.5M in Q2 2021, due to higher personnel costs.
- Three ongoing Phase 1 programs (ORIC-533, ORIC-114, ORIC-944) with initial data expected 1H 2023.
- Preclinical data on PLK4 inhibitor program presented at AACR in April 2022.

## SEC filing metadata
- accession: 0000950170-22-016870
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/0000950170-22-016870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017022016870/oric-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016870
- JSON: https://secwatch.observer/filing/0000950170-22-016870.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.